然而，药物球囊的适应证及术后抗栓策略仍存在许多未解之谜。陶凌教授和团队在2024年9月2日曾在《柳叶刀》上报告了REC-CAGEFREE I研究结果，针对药物球囊的适应症进行了探索。而在今年3月31日，他们进一步推进了研究，在《BMJ》中发布了REC-CAGEFREE ...

近日，国际四大顶级医学期刊之一《BMJ》，以“Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE ...

The improvement of our knowledge on the pharmacodynamics of antiplatelet drugs enables the tailoring of the most appropriate antithrombotic therapy to the individual patient and risk situation in ...

While routine treatment with aspirin plus a second anti-clotting drug, known as dual antiplatelet therapy (DAPT), can prevent ...

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

Various clinical, demographic and genetic variables can influence responsiveness to antiplatelet therapy. In 2008, Geisler et al. 10 showed that residual platelet activity in patients with ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open ...

Two years after percutaneous coronary intervention, people at risk of a cardiac event had better outcomes with clopidogrel ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open ...

A step forward in de-escalating treatment The evolution of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has been shaped by the continuous challenge of balancing ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.